Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Retained Earnings (2016 - 2025)

Fortress Biotech has reported Retained Earnings over the past 13 years, most recently at -$734.1 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$734.1 million for Q4 2025, up 0.92% from a year ago — trailing twelve months through Dec 2025 was -$734.1 million (up 0.92% YoY), and the annual figure for FY2025 was -$734.1 million, up 0.92%.
  • Retained Earnings for Q4 2025 was -$734.1 million at Fortress Biotech, down from -$730.1 million in the prior quarter.
  • Over the last five years, Retained Earnings for FBIO hit a ceiling of -$491.6 million in Q1 2021 and a floor of -$751.5 million in Q1 2025.
  • Median Retained Earnings over the past 5 years was -$683.1 million (2023), compared with a mean of -$650.7 million.
  • Biggest five-year swings in Retained Earnings: fell 18.07% in 2022 and later rose 0.92% in 2025.
  • Fortress Biotech's Retained Earnings stood at -$547.5 million in 2021, then decreased by 15.85% to -$634.2 million in 2022, then fell by 9.56% to -$694.9 million in 2023, then dropped by 6.62% to -$740.9 million in 2024, then increased by 0.92% to -$734.1 million in 2025.
  • The last three reported values for Retained Earnings were -$734.1 million (Q4 2025), -$730.1 million (Q3 2025), and -$736.0 million (Q2 2025) per Business Quant data.